
![]() |
|||||||||||||
WJPR Citation Report
|
| All | Since 2021 | |
| Citation | 9186 | 4781 |
| h-index | 32 | 25 |
| i10-index | 256 | 108 |
NEXT-GENERATION PHARMACEUTICAL INNOVATIONS IN MENINGOCOCCAL DISEASE: PRECISION VACCINE DELIVERY, NANOTECHNOLOGY-ENABLED THERAPEUTICS, AND ADVANCED FORMULATION ENGINEERING
D. Steven Paul, V. Sudheer, B. Mastan, Prasanna Kumar Desu, Anusha Raouri, Kasietti Ashok Babu, Yaparthi Suneetha, David Raju Busi*
Abstract Meningococcal disease is a serious health issue worldwide. It is caused by Neisseria meningitidis which can cause meningitis and meningococcal infection, both which can be life threatening. Vaccination, antimicrobial therapy and supportive medical care have improved but the condition still causes significant morbidity and mortality due to its rapid progression, changing epidemiology, antibiotic resistance and limitations of modern vaccine methods. This review covers novel pharmaceutical technologies for the prevention, diagnosis and treatment of meningococcal disease, including precision vaccine delivery, nanotechnology-enabled therapeutics and advanced formulation engineering. Precision vaccine approaches such as genomic surveillance, antigen matching, reverse vaccinology and structural vaccinology can improve vaccine selection and broader protective immune responses. Using nanotechnology based on delivery systems such as liposomes, lipid nanoparticles, polymeric nanoparticles and nanoemulsions are being studied to improve drug delivery, enhance antigen stability, provide controlled drug release and possibly improve therapeutic targeting . In addition, sophisticated formulation approaches including microencapsulation, lyophilization, spray drying, stabilizer-assisted formulations and controlled-release systems may enhance product stability, shelf life, patient acceptability and distribution. To control diseases, it is mandatory to integrate vaccination, early detection, antimicrobial treatment and modern drug delivery technologies. Safety, toxicity, clinical efficacy, regulatory clearance, manufacturing capacity, cost and accessibility remain important challenges to consider. Future research must target the development of pharmaceutical technologies which are safe, effective, stable and cost-effective, supported by relevant preclinical and clinical investigations. Overall, these emerging innovations hold great promise for improving the prevention and management of meningococcal disease and for improving public health outcomes worldwide. Keywords: Meningococcaldisease, Neisseria meningitidis, Precision vaccine delivery, Nanotechnology, Nanocarriers, Advanced formulation engineering, Controlled drug release, Vaccine development. [Full Text Article] [Download Certificate] |
